Rituximab in the Treatment of Minimal Change Nephropathy and Idiopathic Focal Segmental Glomerulosclerosis:A Rapid Health Technology Assessment
OBJECTIVE To evaluate the effectiveness,safety,and economy of rituximab in the treatment of minimal change disease(MCD)and idiopathic focal segmental glomerulosclerosis(FSGS).METHODS CNKI,PubMed and other databases were systematically searched.Two researchers conducted data process and analysis.RESULTS A total of 1 HTA report,6 systematic reviews/Meta-analysis,and 1 economic study were included.In terms of effectiveness,rituximab had significant efficacy in the treatment of primary and steroid-dependent or frequently relapsing MCD and FSGS,and the efficacy in the treatment of recurrent MCD and FSGS after kidney transplantation was unknown.In terms of safety,the incidence of adverse events was low.In terms of economy,the annual medical expenses of rituximab were comparable to those of the calcineurin inhibitor(CNI).CONCLUSION Rituximab has significant efficacy in adult patients with primary and steroid-dependent or frequently relapsing MCD and FSGS,and the level of ADR is low.The economy still needs to be further evaluated in conjunction with more authoritative research.
rituximabminimal change diseaseidiopathic focal segmental glomerulosclerosisrapid health technology assessment
NETL
NSTL
万方数据
